Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma

In this report, we provide a comprehensive review on the preclinical and clinical investigations conducted in development of the next-generation immunomodulatory drug (IMiD) pomalidomide for the treatment of relapsed/refractory multiple myeloma (MM). We consulted PubMed, MEDLINE, ASH, ASCO annual sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Chanan-Khan, A A, Swaika, A, Paulus, A, Kumar, S K, Mikhael, J R, Rajkumar, S V, Dispenzieri, A, Lacy, M Q
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789204/
https://www.ncbi.nlm.nih.gov/pubmed/24013664
http://dx.doi.org/10.1038/bcj.2013.38

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789204/
https://www.ncbi.nlm.nih.gov/pubmed/24013664
http://dx.doi.org/10.1038/bcj.2013.38

Ejemplares similares